Novo Nordisk shares plummeted more than 2% on Friday after it was learned that a preprint published on medRxiv claims there is a link between Ozempic and a rare vision condition.
The new study was conducted by a group of scholars from Norway and Denmark and claims diabetes patients who used Ozempic were more than twice as likely to be diagnosed with the rare condition NAION.
At 11:15 am ET, Novo Nordisk's shares went down by 2.49% to sell at $105.86.
